FDA clears AI tool to detect 14 conditions

Aidoc, a well-funded radiology AI company, on Wednesday announced it received FDA clearance for a  a tool that can triage 14 critical findings in a single abdominal CT scan: liver injury, spleen injury, bowel obstruction, appendicitis, and more.

As my colleague Katie Palmer reports, the new AI hints at a coming future. More developers are experimenting with large vision models that can be used to identify many different conditions from a single x-ray, MRI, or CT scan. This may require new regulatory approaches from FDA which right now evaluates indications one at a time.

While creating a single product that can scan for many conditions may simplify workflows for radiologists who must juggle a growing arsenal of technology at their disposal, it could also amplify risks, including that an AI will falsely identify signs of a condition a patient doesn’t have.

Read more here

Cancer

Benefit from Moderna’s skin cancer immunotherapy endures

From STAT’s Matthew Herper: Moderna and Merck said that adding the cancer immunotherapy intismeran autogene to Keytruda slowed the rate of relapse or death in patients with metastatic melanoma by 51% after five years.

That is exactly the benefit that was seen in an analysis of the treatment, an mRNA therapy that primes patients’ immune systems to attack tumors, at three years in the same 157-patient clinical trial. The original results of the study were published in the Lancet in 2024. Volunteers were given either the new therapy and Keytruda alone after surgery to remove their cancer.

The durable benefit relative to Keytruda indicates that patients are continuing to benefit. Moderna did not respond to requests to clarify the absolute rate at which patients on the therapy are going without disease recurrence or death. Merck and Moderna have fully enrolled a Phase 3 study of the treatment in melanoma and are enrolling separate Phase 3 studies in lung cancer.

from AXIOS:

Vaccine changes pit docs against feds
By Caitlin Owens
Illustration of a giant syringe pinning a white doctor's coat to a wall.
Illustration: Aïda Amer/Axios
Parents around the country are suddenly confronting a bizarre dynamic: Their pediatrician’s vaccine advice doesn’t match that of the federal government.

Why it matters: Kids’ health is at stake at a time when vaccine-preventable diseases are on the rise and trust in public health institutions is already low.

State of play: Doctors and health systems are ignoring the Trump administration’s new and narrower childhood vaccine recommendations and sticking to the old schedule.

  • Coalitions of blue states and local health officials are also rejecting the changes, which dropped six shots — including those for the flu, rotavirus and hepatitis — from the recommended list and instead urged parents to consult providers about the shots.
  • At least 19 states have said they won’t follow the new CDC schedule and will instead follow the American Academy of Pediatrics’ recommendations, which continue to call for the same immunizations CDC did before Trump’s current term.
  • And more than 200 medical, public health and patient advocacy groups signed onto a letter urging Congress to investigate the schedule changes. Some — including the American Academy of Pediatrics — are suing to reverse them.

What they’re saying: “This is the first time in memory that parents aren’t able to count on federal health agencies to provide evidence-based vaccine recommendations,” said Michael Osterholm, director of the the Center for Infectious Disease Research and Policy and the Vaccine Integrity Project.

Between the lines: The Trump administration has stressed that all of the previously recommended vaccines will still be covered by insurance, and that whoever wants them will be able to get them.

  • But parents now are in the unfamiliar position of deciding whether their child should receive certain vaccinations, which necessitates choosing which authority figures they’ll listen to.
  • HHS Secretary Robert F. Kennedy Jr. — a leading anti-vaccine activist before becoming health secretary — has suggested that parents figure it out themselves.

Keep reading

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
Congress pushes back against Trump’s NIH cuts
By Peter Sullivan
Illustration of a hand pouring out a test tube full of liquid money.
Illustration: Allie Carl/Axios
Republicans and Democrats are using the latest government funding package to push back against President Trump’s proposed cuts to NIH — and limit the administration’s influence over biomedical research grants.

Why it matters: The bipartisan sentiment shows that efforts to find new cures still have strong support on Capitol Hill after a turbulent year for the agency.

Driving the news: The health care portion of the spending package released early Tuesday includes $48.7 billion for NIH — an increase of $415 million, and a far cry from the roughly 40% cut in President Trump’s budget request.

  • There’s also language aimed at limiting a Trump administration policy that funded multiple years of a grant all at once. Critics say the policy reduced the number of awards made.
  • The spending bill would also keep language blocking NIH from imposing a 15% cap on research universities and institutions’ overhead and administrative costs.
  • Beyond NIH, it would additionally revive a program that prioritizes reviews of treatments for rare pediatric diseases that expired in part at the end of 2024 and was left out of subsequent funding packages.

Yes, but: NIH grant cancellations, program cuts and other unilateral moves by the administration are unlikely to stop.

Read more

from AXIOS:

Charted: The big measles surge
By Adriel Bettelheim
A line chart of the cumulative U.S. measles cases for each year from 2022 to 2026. 2025 had the most cases at 2,242, followed by 2024 (285 cases), 2022 (121 cases) and 2023 (59). As of January 13, 2026, there have been 171 cases.

Data: CDC; Chart: Axios Visuals

This chart shows what it looks like to hit a 30-year high in measles cases — and why the U.S. is on track to lose its measles “elimination status.”

Why it matters: We’ve all heard that cases are on the rise, but the reality is that they’re skyrocketing.

  • It started with an outbreak in West Texas, and now infections are reported in nine states and hundreds are in quarantine due to a major surge in South Carolina.
  • More than 9 out of 10 cases were among unvaccinated people or those with unknown vaccination status, per the CDC.

What they’re saying: On Tuesday, Ralph Abraham, a top CDC official, told reporters that the end of the measles elimination status in the U.S. would be “just the cost of doing business, with our borders being somewhat porous [and] global and international travel,” Stat reported.

What we’re watching: The risk of spillover increased with holiday travel. North Carolina and Ohio reported infected individuals who traveled to the outbreak epicenter in South Carolina.

Share this

Facebook
Twitter
LinkedIn
Pinterest
Email

Related Posts

What is hyperphosphatemia?

Symptoms Causes Diagnosis Treatment Prevention Outlook Excess phosphate in the blood is known as hyperphosphatemia. The most common cause is kidney disease, but other conditions

Read More »
Scroll to Top